Inicio › Cáncer de pulmón › Washington › Seattle
Ensayos clínicos de Cáncer de pulmón en Seattle, WA
34 estudios para Cáncer de pulmón buscan participantes en centros de Seattle y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
ReclutandoFase 2/3
- Fred Hutchinson Cancer Center, Seattle
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
ReclutandoFase 3
- Swedish Medical Center-First Hill, Seattle
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
ReclutandoFase 3
- Swedish Medical Center-First Hill, Seattle
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
ReclutandoFase 1/2
- Virginia Mason Medical Center, Seattle
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
ReclutandoEstudio observacionalSe aceptan voluntarios sanos
- Swedish Medical Center-Ballard Campus, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- Swedish Medical Center-First Hill, Seattle
- y 1 más
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
ReclutandoFase 2
- Local Institution - 0086, Seattle
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
ReclutandoFase 3
- Swedish Medical Center, Seattle
- VA Puget Sound Health Care System, Seattle
An Educational Intervention (Lung Toolkit) for Improving Knowledge About Lung Cancer and Screening Among American Indian and Alaskan Native Cigarette Smokers, Lung PATHS Trial
ReclutandoSe aceptan voluntarios sanos
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Restorative Justice-Based Lung Cancer Screening Decision-Making Support Intervention Tailored for Black Individuals to Increase Lung Cancer Screening Among Black Community Members, RESTORE Trial
ReclutandoSe aceptan voluntarios sanos
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
ReclutandoFase 2
- Research Site, Seattle
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
ReclutandoFase 1/2
- Avenzo Therapeutics Recruiting Site, Seattle
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
ReclutandoFase 1/2
- Fred Hutchinson Cancer Research Center, Seattle
SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
ReclutandoFase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
ReclutandoFase 2
- Swedish Medical Center-First Hill, Seattle
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
ReclutandoFase 1/2
- University of Washington, Fred Hutchinson Cancer Center, Seattle
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
ReclutandoFase 1
- Fred Hutchinson Cancer Center, Seattle
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
ReclutandoFase 3
- University of Washington - Fred Hutchinson Cancer Center, Seattle
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
ReclutandoFase 1/2
- Swedish Medical Center, Seattle
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer
ReclutandoFase 1
- Fred Hutchinson Cancer Center, Seattle
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
ReclutandoFase 3
- Virginia Mason Medical Center, Seattle
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
ReclutandoFase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer
Reclutando
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
ReclutandoFase 1
- Fred Hutchinson Cancer Center, Seattle
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
ReclutandoFase 1
- Xencor Investigative Site, Seattle
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
ReclutandoFase 1
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
ReclutandoFase 1/2
- Fred Hutch Cancer Center, Seattle
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
ReclutandoFase 2
- Seattle Cancer Care Alliance, Seattle
SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer
ReclutandoFase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
ReclutandoFase 1/2
- Fred Hutchinson Cancer Center, Seattle
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
ReclutandoFase 2
- Fred Hutchinson Cancer Center, Seattle
- Swedish Medical Center-First Hill, Seattle
- FHCC at Northwest Hospital, Seattle
- y 1 más
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
ReclutandoFase 1/2
- Virginia Mason Medical Center, Seattle
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
ReclutandoFase 1
- Fred Hutchinson Cancer Center, Seattle
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
ReclutandoEstudio observacional
- Massive Bio SYNERGY-AI site, Seattle
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
ReclutandoFase 1/2
- Fred Hutch Cancer Center, Seattle
Más información sobre Cáncer de pulmón en MedlinePlus
Ensayos de Cáncer de pulmón en otras ciudades
- Houston, TX78 estudios
- Boston, MA63 estudios
- New York City, NY60 estudios
- Los Angeles, CA45 estudios
- Chicago, IL43 estudios
- Arlington, VA42 estudios
- Washington, DC41 estudios
- Baltimore, MD41 estudios
- Nashville, TN39 estudios
- St. Louis, MO37 estudios
- Columbus, OH36 estudios
- Philadelphia, PA36 estudios
Otros estudios en Seattle
- Cáncer de pulmón de células no pequeñas55 estudios
- Cáncer (todos los tipos)48 estudios
- Cáncer de próstata45 estudios
- Leucemia mielógena aguda40 estudios
- Cáncer metastásico39 estudios
- Cáncer de seno37 estudios
- Cáncer del colon y del recto35 estudios
- Cáncer de ovario29 estudios
- Cáncer de páncreas22 estudios
- Mieloma múltiple22 estudios
- Leucemia linfoblástica aguda22 estudios
- Leucemia linfocítica crónica22 estudios
De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.